NCT05891964View on ClinicalTrials.gov

Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

June 5, 2022

Study Completion Date

July 10, 2022

Conditions
Plaque Psoriasis
Interventions
DRUG

Secukinumab Injection

Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.

Trial Locations (1)

75510

Jinnah Post graduate Medical centre, Karachi

All Listed Sponsors
lead

Jinnah Postgraduate Medical Centre

OTHER_GOV